<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044095</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR1525</org_study_id>
    <secondary_id>HSRRB No. A-15223</secondary_id>
    <nct_id>NCT01044095</nct_id>
  </id_info>
  <brief_title>Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus</brief_title>
  <official_title>Evaluation of In Vitro Cross-Reactivity With Avian Influenza H5N1 Virus in Healthy Volunteers Vaccinated With a Prime Boost Regimen of Seasonal Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armed Forces Research Institute of Medical Sciences, Thailand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Armed Forces Research Institute of Medical Sciences, Thailand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, open-label, pilot feasibility study of four 2-dose vaccine
      regimens in healthy volunteers using two commercially available seasonal influenza vaccines
      to compare immune responses and in vitro cross-reactivity against H5N1. Vaccine doses will be
      spaced by approximately 8 weeks to allow for optimal prime boost conditions. Humoral,
      cellular and secretory immune responses will be measured 2 and 4 weeks after each vaccine
      dose and compared with baseline values.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antibody titers</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of 2 doses of seasonal influenza vaccine in healthy adults</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Autologous prime boost regimen 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FluMist® live intranasal vaccine (LAIV) 0.2mL (0.1mL per nostril): 2 doses separated by 8 weeks (+/- 7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous prime boost regimen 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluzone® inactivated seasonal influenza virus vaccine intramuscularly: 2 doses separated by 8 weeks (+7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterologous prime boost regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FluMist® live, intranasal vaccine single dose, followed by Fluzone® inactivated influenza virus vaccine 8 weeks (+/-7 days) later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterologous prime boost regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluzone® inactivated seasonal influenza virus vaccine single dose, followed by FluMist® live, intranasal seasonal influenza vaccine 0.2mL 8 weeks (+/- 7 days) later</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist® live, attenuated, intranasal seasonal influenza vaccine</intervention_name>
    <description>FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)</description>
    <arm_group_label>Autologous prime boost regimen 1</arm_group_label>
    <arm_group_label>Heterologous prime boost regimen 1</arm_group_label>
    <arm_group_label>Heterologous prime boost regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® inactivated influenza virus vaccine</intervention_name>
    <description>Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly</description>
    <arm_group_label>Autologous prime boost regimen 2</arm_group_label>
    <arm_group_label>Heterologous prime boost regimen 1</arm_group_label>
    <arm_group_label>Heterologous prime boost regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-49 years.

          2. Healthy as determined by the PI or designate

          3. Willing to give informed consent.

          4. Willing to attend follow-up appointments and undergo study procedures.

          5. US passport holder residing in Bangkok

          6. If military, have a letter of approval for participation from the chain of command
             (Unit Commander).

        Exclusion Criteria:

          1. History of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine.

          2. Severe or life-threatening reaction to any previous vaccine.

          3. History of chronic respiratory illness, including asthma and sinusitis.

          4. History of heart disease

          5. History of kidney disease

          6. Metabolic disease such as diabetes

          7. Immunocompromised as determined by the PI, or a household contact of an
             immunocompromised individual.

          8. History of Guillain-Barre syndrome.

          9. Blood disease including sickle cell disease and/or bleeding tendency (by history or
             based on medical records).

         10. Any influenza vaccination within the previous 6 months, or any other vaccine within 30
             days of either dose of influenza vaccine.

         11. Pregnant woman or nursing mother or unwilling to use reliable contraception during the
             study period until the final day of follow-up.

         12. Blood donation within the preceding 3 months, or screening hemoglobin value of &lt;12.5
             g/dl.

         13. Receipt of blood products including immunoglobulins within the preceding 3 months.

         14. Receiving any of the following therapies: aspirin, warfarin, theophylline, phenytoin,
             aminopyrine, immunosuppressive drugs,

         15. Receipt of any antiviral agents within 48 hours of vaccine administration.

         16. HIV positive on screening blood tests.

         17. Any other condition that in the opinion of the study investigator warrants exclusion
             from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delia B Bethell, BM BCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Armed Forces Research Institute of Medical Sciences, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>United States Embassy Medical Unit</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0059674</url>
  </link>
  <results_reference>
    <citation>Bethell D, Saunders D, Jongkaewwattana A, Kramyu J, Thitithayanont A, Wiboon-ut S, Yongvanitchit K, Limsalakpetch A, Kum-Arb U, Uthaimongkol N, Garcia JM, Timmermans AE, Peiris M, Thomas S, Engering A, Jarman RG, Mongkolsirichaikul D, Mason C, Khemnu N, Tyner SD, Fukuda MM, Walsh DS, Pichyangkul S. Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial. PLoS One. 2013;8(3):e59674. doi: 10.1371/journal.pone.0059674. Epub 2013 Mar 26.</citation>
    <PMID>23555741</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2010</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <last_update_submitted>July 22, 2013</last_update_submitted>
  <last_update_submitted_qc>July 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seasonal influenza vaccine</keyword>
  <keyword>avian influenza H5N1</keyword>
  <keyword>cross reactivity</keyword>
  <keyword>prime boost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

